NOXXON is publicly traded on Paris’ Euronext Growth exchange (ALNOX.PA). Prior to its listing in 2016, the company was supported by a premier investor base, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure.

Company Information

NOXXON believes that the future of cancer treatment lies in finding optimal combinations of drugs to fight cancer in multiple ways.

Our oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. Read more here.